For Immediate Release
August 12, 2021

SUNSHINE BIOPHARMA'S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN

Montreal, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma Inc. (OTC Pink: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it mapped the mutations found in Delta and the other variants of concern ("VOC") identified to date and determined that the majority of the mutations are in the Spike protein and only a few fall within the genomic sequences that encode nsp3, a multi-domain protein that includes the PLpro enzyme. Serendipitously, no mutations mapped within the domain comprising the PLpro catalytic core. These finding indicate that our PLpro inhibitors currently under development at the University of Georgia would likely be effective against all of the VOC.

The VOC currently recognized by the World Health Organization and the CDC in the United States include the Alpha, Beta, Gamma and Delta variants. All of the mutations of these variants were found to occur outside of the PLpro catalytic domain where our inhibitors function. Mutations falling outside of the catalytic domain of an enzyme are generally considered to be inconsequential to the activity of that enzyme. Based on the crystal structure of PLpro, the contact points of our inhibitors within the catalytic domain of PLpro remain unchanged.

"We are delighted by these findings and look forward to completing our mice studies at the University of Georgia soon," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 4.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making

them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting.

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University's Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com